Please login or register first to view this content.
Psychiatric Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
Lumateperone Under Review for Bipolar Depression
Novel Combination Therapy for Major Depressive Disorder Gets Priority Review
Evekeo ODT Approved for Younger Patients With ADHD
Psilocybin Compared With Escitalopram for Depression
Xywav Gets Priority Review for Idiopathic Hypersomnia
Considerable Neurologic, Psychiatric Morbidity Reported After COVID-19
FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis
Qelbree, a Nonstimulant Treatment for ADHD, Gets FDA Approval
Review Examines Metabolic, Cardiovascular Side Effects of Second-Generation Antipsychotics
FDA: Risk of Arrhythmias With Lamotrigine in Patients With Heart Disease
FDA: Abuse/Misuse of OTC Nasal Decongestant Can Lead to Major Health Complications
Poor Sleep, Burnout Increase COVID-19 Risk in Health Care Workers
Review: ß-Blocker Therapy Not Linked to Depression
Dexmedetomidine Oral Film Gets Breakthrough Tx Status for Acute Agitation With Dementia
Dexmedetomidine Oral Thin Film NDA Submitted for FDA Review
FDA to Review Daridorexant for Insomnia Treatment
Azstarys, a Once-Daily Treatment for ADHD, Gets FDA Approval
FDA to Review Once-Nightly Sodium Oxybate Formulation for Narcolepsy
